Oncgnostics tests are based on epigenetic changes, so called DNA methylations which are characteristic for cancer cells. These highly informative biomarkers, validated and patented by us, represent the core of our products and provide the basis for our activities.
The Oncgnostics strategy focuses on the IVD test development field at, after test validation and initial preclinical trials, cooperation with international partners. After registration, products will be marketed directly or through licensing to cooperation or distribution partners.
BioPortUSA was engaged by the management team at Oncgnostic to help them better understand and develop a market access strategy to insure reimbursement of the product. “We selected to work with BioPortUSA because we felt they had the expertise for our particular test and we knew how important reimbursement was going to be for a successful launch into the U.S. marketplace” said Dr Peter Haug, Head of Business Development and Licensing.
Learn more about Oncgnostics on their website oncgnostics.com.
